Polyrizon shares surge 92.05% intraday after successful PL-14 manufacturing milestone enables clinical trial supply and commercial scale-up.

Polyrizon surged 92.05% intraday following a pivotal manufacturing milestone for its PL-14 allergy blocker, announced on December 2, 2025. The company validated large-scale production of its hydrogel-based nasal spray with a contract development organization, meeting specifications for consistency, stability, and quality. This achievement enables clinical trial supply in 2026 and de-risks commercial scalability, addressing a key operational hurdle. The news reinforced investor confidence in Polyrizon’s ability to advance its non-pharmacological allergy and viral protection platform, with market focus on the $11.14 billion allergic rhinitis sector. Multiple reports highlighted the milestone as a catalyst, directly correlating with the intraday price spike.